Beyond glycemic control: differential effects of empagliflozin and sitagliptin on insulin sensitivity and a shared increase in adropin in type 2 diabetes

Otbah Salim Taha, Golnaz Azami, Lotfollah Saed, Mohammad Saeed Hakhamaneshi, Heresh Moridi · 2026

Read Beyond glycemic control: differential effects of empagliflozin and sitagliptin on insulin sensitivity and a shared increase in adropin in type 2 diabetes by Otbah Salim Taha, Golnaz Azami, Lotfollah Saed, Mohammad Saeed Hakhamaneshi, Heresh Moridi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13418427.txt.

Description

Otbah Salim Taha and co-authors report a 2026 trial that compares two added drugs for type 2 diabetes. Adults whose blood sugar stayed high on metformin alone got either empagliflozin or sitagliptin for twelve weeks. The team tracked a blood protein called adropin, insulin response, sugar control, fats, and swelling markers.

Both drugs raised adropin by a like amount. Both also cut insulin resistance and long term sugar levels, with larger drops on empagliflozin. That drug also cut fasting insulin and blood fats more. A swelling marker fell in both groups. The authors say the two drugs share some gains but differ in how they shift metabolism.

Catalog record

CREATOROtbah Salim Taha, Golnaz Azami, Lotfollah Saed, Mohammad Saeed Hakhamaneshi, Heresh Moridi
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE94 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13418427

Browse the full library · About the Tower of Babel